Globoid Cell Leukodystrophy, GLD (Hereditary Disease of the White Matter of the Brain, Krabbe Disease) in Dogs

  • Occurrence: very rare
  • Location of illness: Back/Tail, Head/Neck
Author: Dr. med. vet. Gisa Löwe | Last modified: 06.11.2025

Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a hereditary neurological disorder in dogs that leads to progressive damage to the white matter of the brain and spinal cord. This disease is characterized by the absence or malfunction of a specific enzyme that is crucial for the normal myelination of nerve fibers.

The most important facts at a glance

Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a genetic disease in dogs caused by a deficiency of the enzyme galactocerebrosidase (GALC). This enzyme is responsible for breaking down certain fats in the myelin sheath that surrounds nerve fibers. Without a functioning GALC enzyme, toxic substances accumulate, leading to damage to the myelin sheath and neurological disorders. The disease is inherited as an autosomal recessive trait, meaning a dog must inherit two defective genes to be affected. Symptoms often appear in young dogs and include tremors, uncoordinated gait, muscle wasting, and in some cases Paralysis or seizure-like episodes. Diagnosis is made through clinical observations, genetic tests, and biochemical analyses. Imaging techniques such as MRI can show the extent of the damage. There is no cure; treatments aim to alleviate symptoms and improve quality of life, for example through medication and physical therapy. Bone marrow transplants are rare and risky. The prognosis is poor as the disease progresses rapidly and often leads to Death. Prevention through genetic testing and responsible breeding practices is crucial. Research approaches focus on gene therapies and enzyme replacement therapies to offer better treatment options in the future.

Causes

Globoid cell leukodystrophy is a lysosomal storage disease caused by a deficiency of the enzyme galactocerebrosidase (GALC). This enzyme is responsible for breaking down certain fats called galactolipids, which are an essential component of the myelin sheath. The myelin sheath is the protective covering that surrounds nerve fibers and is required for the proper transmission of nerve impulses.

In the absence of the functioning GALC enzyme, galactolipids accumulate, especially psychosine, which is toxic to oligodendrocytes, the cells that produce myelin. The result is demyelination, which leads to disruption of nerve conduction and neuronal dysfunction.

The cause of the absence or malfunction of the GALC enzyme is genetic. GLD is inherited as an autosomal recessive trait. This means that a dog must inherit two copies of the defective gene—one from each parent—to develop the disease. Carriers, who have only one copy of the defective gene, do not show symptoms but can pass the disease on to their offspring.

Symptoms

Rare symptoms:

The symptoms of globoid cell leukodystrophy vary depending on the severity and progression of the disease but often appear at a young age. The first signs include weakness and instability, especially in the hind legs, which can lead to an unsteady, staggering gait.

As the disease progresses, neurological symptoms such as tremors, muscle spasms, Blindness, and cognitive impairments occur. The dogs may have Difficulty standing or walking and often show Behavioral changes such as increased Irritability or lethargy.

In advanced stages, complete Paralysis, Convulsions, and loss of cognitive abilities can occur. The symptoms usually worsen rapidly, leading to a significant decline in quality of life.

Diagnosis

The diagnosis of globoid cell leukodystrophy is based on a combination of clinical signs, genetic tests, and specific biochemical analyses. GLD may be suspected in young dogs with the neurological symptoms described, especially in breeds that are predisposed to the disease.

Genetic tests can be performed to confirm the presence of the defective GALC gene. These tests are crucial for diagnosis as they help identify carriers and affected dogs. Biochemical tests to measure GALC enzyme activity in white blood cells or skin cells can also be performed to support the diagnosis.

Imaging techniques such as MRI can be used to assess the degree of demyelination and damage to brain structures. A definitive diagnosis can be achieved through a combination of these methods.

Therapy

Currently, there is no cure for globoid cell leukodystrophy, and treatment focuses primarily on relieving symptoms and supporting the quality of life of the affected dog. This may include administering medications to control Convulsions and muscle spasms, as well as physical therapy to support mobility.

In some cases, a bone marrow transplant may be considered to support the production of the missing enzyme. However, this treatment is invasive, expensive, and carries significant risks, which is why it is rarely used.

Research into gene therapies and enzyme replacement therapies is ongoing, but these approaches are still in the experimental stages and are not currently widely available.

Prognosis and follow-up care

The prognosis for dogs with globoid cell leukodystrophy is unfortunately poor. The disease progresses rapidly and usually leads to severe disability and Death within a few months of the onset of the first symptoms. The quality of life of affected dogs deteriorates rapidly, often necessitating humane euthanasia.

While early detection of the disease can help alleviate symptoms and improve quality of life in the short term, it ultimately does not change the progression of the disease.

Prevention

Since globoid cell leukodystrophy is genetic, the key to prevention lies in genetic testing and responsible breeding practices. Dogs that are carriers of the defective gene should not be used for breeding to prevent the disease from being passed on.

Breeders should perform genetic tests on potential parents to ensure that they are not carriers. This can help minimize the risk of puppies being born with the disease.

Education and genetic counseling can also play an important role in raising awareness of the disease and reducing the spread of the defective gene in the population.

Outlook on current research

Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a genetic disorder that affects the nervous system of dogs. Research on GLD in dogs focuses on understanding the genetic basis, developing diagnostic methods, and testing new treatment approaches. The main focus is on studying the mutations in the GALC gene, which is responsible for the production of the enzyme galactocerebrosidase. This enzyme plays a crucial role in the breakdown of certain lipids in the nervous system.

A significant advance in research is the development of genetic tests that make it possible to identify carriers of the disease and diagnose affected dogs early. These tests are particularly important for breeders as they help prevent the spread of the disease through selective breeding programs. The identification of the genetic markers for GLD has helped to deepen the understanding of the disease mechanisms and to define specific therapeutic goals.

Current research projects also focus on the development of gene therapies to correct or replace the defective GALC gene. In preclinical studies in animal models, gene therapy approaches have shown promising results, including prolonging the lifespan and improving the neurological functions of affected animals. These approaches involve the use of viral vectors to deliver the corrected gene directly into the nervous system.

In addition, research is being conducted on the development of enzyme replacement therapies, in which the missing or defective enzyme is supplied from the outside to alleviate the symptoms of the disease. Although these therapies are currently still in the experimental phase, they could be a valuable addition to existing treatment strategies in the future.

Research centers around the world are also working on developing new drugs that could slow down or prevent the breakdown of nerve cells. These drugs aim to inhibit the inflammatory processes associated with the Death of oligodendrocytes, the cells that form the myelin sheath in the brain. These inflammatory processes contribute significantly to the progression of the disease.

Another focus of research is on improving the quality of life of dogs with GLD. This includes the development of supportive therapies that promote the mobility and general well-being of the animals. Physical therapy, nutritional adjustments, and the use of assistive devices can help improve the quality of life of affected dogs.

In summary, research on GLD in dogs is steadily advancing and has produced promising approaches for the treatment and management of the disease. Advances in genetic and molecular research offer hope for more effective therapies and a better future for affected dogs.

Frequently asked questions (FAQs)

  1. What is globoid cell leukodystrophy in dogs? Globoid cell leukodystrophy, also known as Krabbe disease, is an inherited disorder that affects the white matter of the brain in dogs. It is caused by a genetic mutation that leads to a deficiency of the enzyme galactocerebrosidase, which leads to an accumulation of harmful substances in the nervous system.

  2. Which breeds are most commonly affected? The disease is more common in certain breeds, including West Highland White Terriers, Cairn Terriers, and Irish Setters. However, other breeds can also be affected. It is important that breeders perform genetic tests to minimize the risk of the disease.

  3. How is the disease diagnosed? The diagnosis of globoid cell leukodystrophy is usually made through genetic tests that detect the presence of mutations in the GALC gene. Early diagnosis is crucial in order to take appropriate treatment measures.

  4. What symptoms does a dog with GLD show? The most common symptoms include movement disorders, Muscle weakness, coordination problems, and Behavioral changes. In the advanced stage, Convulsions can also occur. The symptoms generally worsen over time.

  5. Is there a cure for GLD? Currently, there is no cure for globoid cell leukodystrophy. However, research is working intensively on new therapeutic approaches, including gene therapy and enzyme replacement therapy, to treat the disease or alleviate the symptoms.

  6. How is the disease treated? The treatment focuses on alleviating the symptoms and improving the dog’s quality of life. This includes physical therapy, medications to control Convulsions, and supportive care. In some cases, experimental therapies may be considered.

  7. How can I, as a dog owner, help prevent the disease? As a dog owner, you can help prevent the disease by opting for genetic testing and promoting responsible breeding practices. If you want to buy a dog, you should make sure that the breeders have carried out genetic tests.

  8. How long do dogs with GLD live? Dogs with GLD unfortunately have a shortened life expectancy. Most affected dogs show symptoms within the first six months, and the disease progresses rapidly, often leading to early Death. However, the exact lifespan can vary.

  9. Can the disease be transmitted to humans? No, globoid cell leukodystrophy in dogs is not transmissible to humans. It is a specific genetic disease that only affects certain animals.

  10. Where can I get more information about GLD? You can get more information about globoid cell leukodystrophy from your veterinarian or specialized veterinary clinics. In addition, many universities and research centers specializing in veterinary genetics offer resources and advice.

Content
Download/Print